ArticleHepatitis monthly2014
Management of liver hemangioma using trans-catheter arterial embolization.
Article in Hepatitis monthly, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness of Transarterial Embolization in Treatment of Symptomatic Hepatic Hemangiomas: Systematic Review and Meta-analysis.Cardiovascular and interventional radiology · 2021Pooled it
- Clinical outcomes of combined transarterial chemoembolization and microwave ablation for hepatic hemangiomas: a comparative analysis of large versus. giant tumors.BMC gastroenterology · 2025Article
- A novel and effective strategy for the treatment of large hepatic hemangioma: combining preoperative embolization with laparoscopic-assisted and ultrasound-guided ablation.World journal of surgical oncology · 2025Article
- Endovascular treatment of giant hepatic hemangiomas: a systematic review and meta-analysis.Jornal vascular brasileiro · 2025Review
- Giant hepatic hemangioma treatment with transcatheter arterial embolisation and transcatheter arterial chemoembolisation; Comparative resultsTurkish journal of medical sciences · 2021Article
- A Nomogram Model for Predicting the Response to Transcatheter Arterial Embolization in Patients With Symptomatic Hepatic Hemangioma.Frontiers in molecular biosciences · 2021Article
- Extended liver resection including hypertrophy concept with portal venous embolisation for giant haemangioma. Too much surgery?Annals of hepato-biliary-pancreatic surgery · 2020Article
- Review
- Article
- Transarterial (Chemo-)Embolization and Lipiodolization for Hepatic Haemangioma.Cardiovascular and interventional radiology · 2019Review
- Transarterial embolization for the treatment of complicated liver hemangiomas: A report of two cases and review of the literature.Clinical and molecular hepatology · 2018Article
- Indications for liver surgery in benign tumours.European surgery : ACA : Acta chirurgica Austriaca · 2018Article
- Superselective Transarterial Chemoembolization as an Alternative to Surgery in Symptomatic/Enlarging Liver Hemangiomas.World journal of surgery · 2017Article
- Radiofrequency ablation for hepatic hemangiomas: A consensus from a Chinese panel of experts.World journal of gastroenterology · 2017Review
- Observational
- Hepatobiliary Tumors: Update on Diagnosis and Management.Journal of clinical and translational hepatology · 2015Review
- Embolization of Liver Hemangiomas.Hepatitis monthly · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHemangioma, a congenital vascular malformation, is the most common benign liver lesion that is usually remain stable subsequently requiring not treatment; however, complications such as abdominal pain or fullness, coagulation disturbances, and inflammatory syndrome may occur, demanding a specific treatment of hemangioma.
objectivesTo assess the safety, feasibility and efficacy of trans-catheter arterial embolization (TAE) for the treatment of Liver hemangioma. PATIENTS AND
methodsTAE was performed on 20 patients with liver hemangioma. The embolic agent used was polyvinyl alcohol (PVA) particles (300-400 micron, Jonson and Johnson Cordis, USA). All patients were followed up for 6 months. Imaging was carried out and patients were also evaluated symptomatically through telephone interview by a physician.
resultsTwenty patients aged from 21 to 63 years (mean: 46.8, SD: 10.26) were included in this study. Post embolization syndrome, including abdominal pain, fever, and leukocytosis occurred in one patient 1 week after TAE and lasted for 3 days. No serious adverse event and TAE-related death was observed. None of the patient underwent another intervention including surgery. During follow up interval, decreased episode of abdominal pain was documented in all patients who had pain. Tumor enlargement was also stopped during the follow up. The average diameter of tumors was 97.00 mm (range: 25-200 SD: 47.85) and 88.95 mm (range: 23-195 SD: 43.27) before and after embolization, respectively. Comparison of images before and after TAE revealed statistically significant decrease in the size of lesion (P value: 0.004, t: 3.31).
conclusionsOur findings indicate that TAE is a safe and efficient procedure for the treatment of liver hemangioma. Further studies with larger sample sizes are required to support therapeutic effects of TAE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.